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Nikolaos Papoutsoglou*, Maximilian Burger and Hubertus RiedmillerAbstract
Background: Metastatic melanoma of the seminal vesicles is a very rare clinical entity and has been reported only
once until today in a patient suffering from concomitant HIV infection 12 years ago.
Case presentation: We report a case of persistent, painless hemospermia in a young Caucasian caused by
metastatic malignant melanoma of the right seminal vesicle. The diagnosis was established by magnetic resonance
imaging and transrectal ultrasound-guided biopsy. In the subsequent diagnostic workup the primary location of the
tumor remained unknown but concomitant pulmonary, hepatic and supraclavicular lymph node metastases have
been detected. Despite immediate chemotherapy initiation the patient finally succumbed to his progressive disease
six months later.
Conclusions: Malignant melanoma should be considered as a rare differential diagnosis of hemospermia after
common causes have been ruled out.
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Metastatic melanoma of the seminal vesicles is ex-
tremely rare. In this manuscript we report a case of per-
sistent hemospermia in a young Caucasian caused by
metastatic malignant melanoma of the right seminal
vesicle. The first case of metastatic melanoma of the
seminal vesicles was reported 12 years ago in a patient
with concomitant HIV infection and brain metastases.
Pelvic magnetic resonance and ultrasound-guided biopsy
were both used as diagnostic tools. Although pulmonary,
hepatic and supraclavicular lymph node metastases have
been detected the primary location of the melanoma
remained unidentified. In spite of active treatment the
disease remained progressive and 6 months after the ini-
tiation the patient deceased refusing further treatment.
Even though metastatic melanomas of the seminal vesi-
cles are extremely rare, hemospermia should be consid-
ered as a symptom of this disease after common causes
have been ruled out.* Correspondence: papoutsoglou@gmail.com
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A forty-year old Caucasian male was referred by his gen-
eral practitioner for urological assessment because of
persisting, painless hemospermia, which had initially
been treated with several courses of oral antibiotics for
almost seven months. The patient denied prior trauma
or genitourinary tract infection. The patient denied a
past medical history of bleeding disorders, hypertension
or malignancy of the urinary tract. On physical examin-
ation there were no signs of malignancy except a moder-
ate swelling of the right inguinal lymph nodes. External
genitalia, the prostate on digital rectal examination, the
vasa deferentia, abdomen and pulmo were found to be
normal. Urinalysis was sterile with a moderate micro-
scopic hematuria of 25 Erythrocytes/μl (normally absent
in urine). Full Blood Count, prostate specific antigen
(PSA) level and clotting was normal. Semen analysis for
the presence of melanospermia was not performed.
Transrectal ultrasound (TRUS) showed a normal pros-
tate of 35 cm3 and a round, hypo echoic, solid mass
measuring 19 × 16 mm within the right seminal vesicle
(Figure 1). The left seminal vesicle appeared normal.
The lesion was further investigated by magnetic reson-
ance imaging (MRI) of the pelvis confirming the ultra-
sound finding (Figure 2).entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Ultrasound of the right seminal vesicle mass.
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patient underwent transrectal ultrasound (TRUS) guided
biopsy of the right seminal vesicle. Histopathology
revealed infiltration of the right seminal vesicle with
strongly pigmented melanoma cells positive for S 100 and
Hematoxylin-Eosin representing metastatic disease and
was negative for Cytokeratines AE1/3 (Figures 3 and 4).
S 100 is a sensitive immunohistochemical marker for
melanoma and belongs to the family of calcium binding
proteins such as calmodulin and troponin C. It is local-
ized in the cytoplasma and the nucleus of the cell and is
divided in two subunits namely S100A and S100B.
Although highly sensitive for melanomas and their me-
tastases, is also expressed in non-melanocytic tumoursFigure 2 Axial T2-weighted MRI of the right seminal vesicle mass.such as Schwannommas, glial and neural cells and Lang-
erhans cells.
Hematoxylin-Eosin staining on the other hand is a typ-
ical histological staining and not an immunohistochemi-
cal marker as S100. It has been in use for more than a
century and is still an essential tool for recognizing vari-
ous tissue types. Hematoxylin has a blue-purple color
and stains nucleic acids. Eosin is pink in color and stains
proteins nonspecifically. Hematoxylin-Eosin staining is
also used for the measurement of tumour thickness,
which is also known as the Breslow thickness, and repre-
sents a main prognostic factor for melanoma.
In our try to locate the primary site of the melanoma,
dermatological assessment and computed tomography
Figure 3 Hematoxylin-Eosin staining (x100).
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While pulmonary, hepatic and supraclavicular lymph
node metastasis were found, the primary site of the mel-
anoma remained unidentified. Since no primary site of
the melanoma could be identified a melanoma of un-
known primary was finally diagnosed.
The case entered our institutional multidisciplinary
tumor board. Following respective recommendation the
patient was included into an adequate clinical trial
(EORTC 18032 Study) [1].
Despite active treatments in both arms the disease
remained progressive. Following a further institutionalFigure 4 Immunostaining of the biopsy specimen with S-100 (x400).multidisciplinary tumor board consensus, the supraclavi-
cular lymph nodes and pulmonary masses were resected
revealing largely necrotic metastases of the malignant mel-
anoma. Subsequently further progression occurred and the
patient refused any further specific therapy. He succumbed
six months later to his progressive disease.
Discussion
Hemospermia is defined as macroscopic presence of
blood in the semen. Most cases are related to iatrogenic,
inflammatory, traumatic or infectious pathologies pro-
voking mucosal irritation, hyperemia and edema of the
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hemospermia is mild and self-limited [2-4].
A detailed history eliciting issues of trauma, infection
and bleeding disorders can narrow the differential diag-
nosis and preclude additional investigations in most pa-
tients with hemospermia. Physical examination in these
patients should include blood pressure measurement,
assessment of the penis, palpation of the vasa deferentia
and digital rectal examination. Further radiographic
workup is indicated only in an uncommon situation of
palpable seminal vesicles or if a midline structure is
noted on digital rectal examination.
Hemospermia secondary to malignancy most often is
related to prostate cancer but even in this circumstance
is rare. The incidence rate of hemospemia in male popu-
lations undergoing screening for prostate cancer has
been reported to be 0,5% [5].
In cases of suspicious masses of the seminal vesicles,
TRUS is the initial diagnostic tool of choice due to
excellent visualization of the seminal vesicles and adja-
cent structures. At the same time it offers the opportun-
ity of performing a TRUS-guided biopsy of the seminal
vesicles for histological confirmation [6]. Additional
radiological evaluation with magnetic resonance imaging
(MRI) and computed tomography (CT) is required to
visualize the exact extend of metastases and concomitant
pelvic pathology [7]. Further treatment of hemospermia
related to metastatic involvement strictly depends on the
underlying cause but is compulsory in any case. A multi-
disciplinary approach focusing in further assessment and
treatment options should be sought.
The CUP-Syndrom comprises a heterogenous group of
metastatic tumors for which no primary site can be
detected. Although most CUP-Syndromes derive from
neuroendocrine carcinomas, metastatic melanomas are
but sporadically detected by metastasis only [8,9].
In our case the primary malignancy has been identified
as melanoma but the initial localization of the tumour
remained unknown.
Only one case of metastatic melanoma of the seminal
vesicles has been published to date. The previous reported
case of hemospermia related to metastasis of a malignant
melanoma of unidentified primary site presented with
metastatic masses in both seminal vesicles with concomi-
tant human immunodeficiency virus infection [10]. This
patient presented with synchronous brain metastases
subject to gamma-knife surgery and adjuvant immuno-
therapy with interferon. This patient died five months
after the initial diagnosis. The initial location of the melan-
oma remained in this case also unknown.
Those two cases may suggest a need to consider
hemospermia as a rare symptom of metastatic malignant
melanoma to the seminal vesicles although we overall be-
lieve that most cases of hemospermia are benign in nature.Conclusions
Malignant melanoma should be considered as a differen-
tial diagnosis of hemospermia after common causes have
been ruled out.
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